SG121733A1 - Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease - Google Patents

Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease

Info

Publication number
SG121733A1
SG121733A1 SG200206008A SG200206008A SG121733A1 SG 121733 A1 SG121733 A1 SG 121733A1 SG 200206008 A SG200206008 A SG 200206008A SG 200206008 A SG200206008 A SG 200206008A SG 121733 A1 SG121733 A1 SG 121733A1
Authority
SG
Singapore
Prior art keywords
alzheimer
disease
treatment
nucleic acid
acid molecules
Prior art date
Application number
SG200206008A
Other languages
English (en)
Inventor
L Kathryn Durham
David L Friedman
Mudiyanselage Athula Ch Herath
Lida H Kimmel
Rajesh Bhikhu Parekh
David M Potter
Christian Rohlff
B Michael Silber
Peter Jeffrey Synder
Holly Daria Soares
Thomas R Stiger
P Trey Sunderland
Robert Reid Townsend
W Frost White
Stephen A Williams
Original Assignee
Pfizer Prod Inc
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Oxford Glycosciences Uk Ltd filed Critical Pfizer Prod Inc
Publication of SG121733A1 publication Critical patent/SG121733A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG200206008A 2001-10-03 2002-10-03 Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease SG121733A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32670801P 2001-10-03 2001-10-03

Publications (1)

Publication Number Publication Date
SG121733A1 true SG121733A1 (en) 2006-05-26

Family

ID=23273328

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200206008A SG121733A1 (en) 2001-10-03 2002-10-03 Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease

Country Status (5)

Country Link
EP (1) EP1408333A3 (fr)
JP (1) JP2003284574A (fr)
AU (1) AU2002330215A1 (fr)
SG (1) SG121733A1 (fr)
WO (1) WO2003028543A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019043A2 (fr) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Marqueurs biologiques permettant le diagnostic de la maladie d'alzheimer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
WO2006029838A2 (fr) * 2004-09-14 2006-03-23 Geneprot Inc. Especes polypeptidiques secretees impliquees dans la maladie d'alzheimer
GB0516058D0 (en) * 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
WO2007072070A1 (fr) * 2005-11-08 2007-06-28 Oxford Genome Sciences (Uk) Ltd Nouvelles proteines isoformes et leur utilisation
EP2289909B1 (fr) 2005-11-30 2014-10-29 AbbVie Inc. Procédé de dépistage, procédé de purification d'oligomères béta non-diffusibles, anticorps sélectifs contre les susdits béta-oligomères non diffusibles, et procédé pour la préparation des susdits anticorps
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
CA2743999A1 (fr) 2008-10-27 2010-06-03 Trustees Of Tufts College Acides nucleiques codant des peptides destines au traitement de blessures, composes antiangiogeniques, et utilisations correspondantes
CN101718745B (zh) * 2009-12-07 2012-10-10 南京农业大学 黄麻根系总蛋白双向电泳方法
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP5837761B2 (ja) * 2010-05-12 2015-12-24 イーエヌ大塚製薬株式会社 クローン病の活動性の分類
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2389199B1 (es) * 2011-04-08 2013-09-17 Consejo Superior De Investigaciones Científicas (Csic) Método de diagnóstico de la enfermedad de alzheimer que emplea sfrp1 como biomarcador.
US20140086836A1 (en) * 2011-05-03 2014-03-27 Mental Health Research Institute Method for detection of a neurological disease
JP6161183B1 (ja) * 2017-02-14 2017-07-12 株式会社日本生物製剤 記憶改善用ペプチド

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
US6132977A (en) * 1998-03-13 2000-10-17 University Of New Mexico Measurement of a CNS protein in cerebrospinal or amniotic fluid
WO2001062785A2 (fr) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
US20020025942A1 (en) * 1991-08-09 2002-02-28 Vernon M. Ingram Novel tau/neurofilament protein kinases
US20020142303A1 (en) * 2000-02-24 2002-10-03 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of Schizophrenia
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5731167A (en) * 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
TR199801650T2 (en) * 1995-04-19 1999-03-22 Acorda Therapeutics MMS n�rit b�y�me mod�lat�rleri ve bile�imleri.
WO1998040748A1 (fr) * 1997-03-14 1998-09-17 Neuromark Diagnostic de troubles neurologiques
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
US6458549B2 (en) * 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
AU6049899A (en) * 1998-09-17 2000-04-17 Trustees Of Columbia University In The City Of New York, The Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
WO2000017349A1 (fr) * 1998-09-22 2000-03-30 Shanghai Second Medical University GENE HsgIII HUMAIN
EP1177298A1 (fr) * 1999-05-07 2002-02-06 ZymoGenetics, Inc. Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme
CA2392514A1 (fr) * 1999-06-10 2000-12-21 Hiroshi Okamoto Proteine se liant a reg
WO2001075454A2 (fr) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
US7314727B2 (en) * 2000-07-21 2008-01-01 Maruha Corporation Methods to facilitate diagnosis of normal pressure hydrocephalus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025942A1 (en) * 1991-08-09 2002-02-28 Vernon M. Ingram Novel tau/neurofilament protein kinases
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
US6132977A (en) * 1998-03-13 2000-10-17 University Of New Mexico Measurement of a CNS protein in cerebrospinal or amniotic fluid
WO2001062785A2 (fr) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
US20020142303A1 (en) * 2000-02-24 2002-10-03 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of Schizophrenia
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMINO ACID SEQUENCE ANALYSES OF NON-AA PROTEINS FROM AMYLOID FIBRILS OF BOVINE KIDNEY, INCREASED HEPATOCYTE GROWTH FACTOR *

Also Published As

Publication number Publication date
JP2003284574A (ja) 2003-10-07
WO2003028543A3 (fr) 2004-02-26
WO2003028543A2 (fr) 2003-04-10
AU2002330215A1 (en) 2003-04-14
EP1408333A2 (fr) 2004-04-14
EP1408333A3 (fr) 2006-10-25

Similar Documents

Publication Publication Date Title
SG121733A1 (en) Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
EP1392287B8 (fr) Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer.
EP1817050A4 (fr) Diagnostic et traitement de la maladie d'alzheimer
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
NO20011409L (no) Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
WO2002070696A3 (fr) Molecules d'acides nucleiques cd109, polypeptides et methodes d'utilisation associees
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
CA2373466A1 (fr) Application du gene codant pour l'aprataxine au diagnostic et au traitement de l'ataxie spinocerebelleuse a debut precoce (avec apraxie oculomotrice et hypoalbuminemie)
GB0128283D0 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of asthma
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
GB0128767D0 (en) Nucleic acid molecules, polypepdides and uses therefor, including diagnosis and treatment of asthma
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease
GB0128183D0 (en) Nucleic acid polypeptides and uses including diagnosis and treatment of ErbB2-related cancer
EP1409004A4 (fr) Proteines isolees humaines de type ras, molecules d'acide nucleique les codant et leurs utilisations
GB0008162D0 (en) Diagnosis and treatment of alzheimer's disease
GB0128761D0 (en) Nucliec acid molecules ,polypeptides and uses therefor,including diagnosis and treatment of liver cancer
GB0128763D0 (en) Nucleic acid molecules polypeptides and uses therefor including diagnosis and treatment of T-cell Leukaemia